BioMed Research International

Biomarkers in Women’s Cancers, Gynecology, and Obstetrics


Publishing date
02 May 2014
Status
Published
Submission deadline
13 Dec 2013

1Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center EMN, Erlangen, Germany

2Department of Medicine, Division of Hematology-Oncology, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA

3Molecular Cancer Epidemiology Laboratory, Genetics and Population Health Division, Queensland Institute of Medical Research, Royal Brisbane Hospital Post Office, Herston, QLD, Australia


Biomarkers in Women’s Cancers, Gynecology, and Obstetrics

Description

The evolution of biomarkers in many diseases has changed diagnostic and therapeutic standards over the last decades. Especially after the publication of the reference genome about 10 years ago, many molecular methods have been developed that have led to the discovery of major pathways in the pathogenesis and the progression of many diseases. Main discoveries have been made in the field of cancer research; however, the application of novel technologies to other diseases in gynecology and obstetrics has shown advancements that are of great potential to improve clinical diagnostics, therapeutics, and patient care. Recently the implementation of new therapies together with companion diagnostics promises to identify patients that will have a specifically high response rate to the applied therapies along with rarer side effects.

We invite investigators to contribute with original research papers as well as review papers that will stimulate the understanding of biomarker use in women’s cancers, gynecology, and obstetrics. We are particularly interested in papers describing the use of biomarkers in clinical and preclinical settings. They should aim at the advancement of molecular genetics and molecular diagnostics and provide new insights into the future of biomarker use in women’s cancers, gynecology, and obstetrics. Potential topics include, but not limited to:

  • Recent developments in prediction of disease risk for healthy women
  • Advances in the use of biomarkers in the field of obstetrics
  • Latest technologies for the discovery of biomarkers
  • Role of signal transduction pathways in women’s cancers, gynecology, and obstetrics
  • Biomarkers for the prognosis and severity of diseases
  • Companion diagnostics for novel therapies
  • Recent advances in biomarker use within clinical trials

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/obgyn/bwc/ according to the following timetable:

BioMed Research International
 Journal metrics
See full report
Acceptance rate8%
Submission to final decision110 days
Acceptance to publication24 days
CiteScore5.300
Journal Citation Indicator-
Impact Factor-
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.